BZBo Zhang

Bo Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bo Zhang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Caizheng Yu

    Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China; Department of Public Health, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China

    3 shared publications
  • Dan-Yun Lai

    Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China

    3 shared publications
  • Feng Wang

    Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Hainan Zhang

    Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China

    3 shared publications
  • He-Wei Jiang

    Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China

    3 shared publications
  • Hong Chen

    Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China

    3 shared publications

Latest Publications

  • Open Access

    Coagulation dysfunction in children with secondary hemophagocytic lymphohistiocytosis: a comprehensive analysis

    by Chaojun Duan, Qing Liao, Jiale Gong, Xiaofang Bai, Xiangdong Xu, Bo Zhang

    Coagulation dysfunction plays a critical role in the pathogenesis and prognosis of secondary haemophagocytic lymphohistiocytosis (sHLH) in children. This study aims to systematically analyze the coagulation profiles in paediatric sHLH patients, evaluate their prognostic value and provide an effective basis for reducing mortality in children with HLH. A total of 209 paediatric patients with sHLH were enrolled in this study. Coagulation parameters at admission were collected and compared across groups stratified by aetiology, prognosis and presence of disseminated intravascular coagulation (DIC). The dynamic evolution of coagulation parameters was analyzed using LOWESS curve fitting. LASSO regression was applied to screen for potential risk factors for DIC in sHLH patients, followed by univariate and multivariate logistic regression to identify independent risk factors. Similarly, Kaplan-Meier survival analysis along with univariate and multivariate logistic regression models were used to determine independent risk factors associated with prognosis in sHLH patients. Paediatric patients with secondary haemophagocytic lymphohistiocytosis (sHLH) presented with significant coagulation abnormalities upon hospital admission, as evidenced by markedly elevated prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), thrombin time (TT) and D-dimer (DD) levels (all p < 0.01). Those with infection-associated HLH demonstrated significantly prolonged PT (p = 0.009), APTT (p < 0.001) and TT (p = 0.0028), along with significantly lower fibrinogen (FIB) levels (p < 0.001), compared to patients with autoimmune-associated HLH. Compared to survivors, deceased HLH patients had significantly higher PT and INR (p < 0.01), as well as significantly elevated DD (p = 0.014). Significant differences were observed in coagulation parameters - PT, INR, APTT, TT, DD, FIB, thrombin-antithrombin complex (TAT) and tissue-type plasminogen activator-inhibitor complex (t-PAIC) - between HLH patients with and without disseminated intravascular coagulation (DIC) (all p < 0.05), and the dynamic changes in these parameters (particularly PT, FIB and DD) also differed notably between the two groups. Neurological involvement, hyper-ferritinaemia and elevated INR were identified as independent risk factors for DIC, while neurological involvement and the presence of DIC itself were independent predictors of mortality in paediatric patients. Coagulation dysfunction serves as a core pathological driver in paediatric sHLH, being especially severe in infection-associated cases. Dynamic monitoring of key coagulation parameters and ferritin levels is crucial for early risk warning and timely intervention. Targeted management of coagulation abnormalities, together with proactive prevention and control of neurological complications, may improve outcomes in paediatric patients.


  • Open Access

    Alert for Imported Malaria in Non-Endemic Areas: A Case Report of Atypical Falciparum Malaria in a Young Child and Diagnostic Experience

    by Jiali Feng, Yang Zhou, Bo Zhang, Ming Huang

    Background: Although China has eliminated indigenous malaria, imported cases, particularly among young and middle-aged workers returning from Africa, constitute a major challenge for current epidemic prevention and control. In contrast, imported malaria in children is extremely rare and often subject to diagnostic delays in non-endemic areas due to atypical clinical presentations. Case presentation: We report a case of a 2-year-11-month-old boy who returned from Sudan, a malaria-endemic region, presenting with fever and diarrhea as the initial symptoms. The case was identified by the laboratory through the blood routine re-examination rules, crucially informed by the patient’s epidemiological history. The diagnosis was ultimately confirmed as Plasmodium falciparum malaria by rapid diagnostic testing and microscopic examination. Conclusion: This diagnostic pathway exemplifies a closed-loop model of “clinical suspicion → targeted laboratory testing → definitive pathogen identification.” It provides a practical framework for the early detection and diagnosis of pediatric imported malaria with atypical presentations in non-endemic areas.

  • Open Access

    Unveiling fatal risk factors: Predicting hemophagocytic lymphohistiocytosis in SFTS patients

    by Bo Zhang, Jia-Le Gong, Hao-Long Zeng, Qin Liao

    Background: Severe fever with thrombocytopenia syndrome (SFTS) is a zoonotic infectious disease with high mortality, and hemophagocytic lymphohistiocytosis (HLH) is one of the rare fatal complications of SFTS. Early prediction of the occurrence of HLH and the identification of prognostic factors in SFTS patients with HLH are crucial for effective clinical management. Methods: Univariate and multivariate logistic regression were used to analyze the demographic characteristics, clinical manifestations at admission and laboratory parameters of 272 SFTS patients. The ROC curve was used to calculate the optimal critical value of each index based on the survival outcomes of patients, and the kinetic characteristics of laboratory markers predicting the prognosis of patients with HLH were analyzed. Results: Decreased platelet count, reduced ALT/AST ratio, elevated LDH, and increased DD were identified as independent risk factors for HLH in SFTS patients. Age, fibrinogen (FIB), and procalcitonin (PCT) were independent risk factors for mortality in SFTS patients with HLH (P < 0.05). The combination of these three factors can effectively predict patient prognosis (AUC = 0.903). Patients aged ≥64 years, with FIB ≤ 2.23 g/L, and PCT ≥ 0.9 ng/ml exhibited higher mortality rates. The dynamic characteristics of PCT and FIB levels significantly differed between the survival and death groups in SFTS patients with HLH. Conclusion: Early laboratory indicators can timely identify HLH complications in SFTS patients. Close monitoring of elderly patients and regular assessment of PCT and FIB levels can effectively reduce mortality.


  • Open Access

    COVID-ONE-hi: The One-Stop Database for COVID-19-Specific Humoral Immunity and Clinical Parameters

    by Zhaowei Xu, Yang Li, Qing Lei, Likun Huang, Dan-Yun Lai, Shu-Juan Guo, He-Wei Jiang, Hongyan Hou, Yun-Xiao Zheng, Xue-Ning Wang, et al.

    Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (named COVID-ONE-hi). COVID-ONE-hi is based on the data that contain the IgG/IgM responses to 24 full-length/truncated proteins corresponding to 20 of 28 known SARS-CoV-2 proteins and 199 spike protein peptides against 2360 serum samples collected from 783 COVID-19 patients. In addition, 96 clinical parameters for the 2360 serum samples and basic information for the 783 patients are integrated into the database. Furthermore, COVID-ONE-hi provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-hi is freely available at www.COVID-ONE.cn.


  • Open Access

    COVID-ONE-humoral immune: The One-stop Database for COVID-19-specific Antibody Responses and Clinical Parameters

    by Zhaowei Xu, Yang Li, Qing Lei, Likun Huang, Dan-Yun Lai, Shu-Juan Guo, He-Wei Jiang, Hongyan Hou, Yun-Xiao Zheng, Xue-Ning Wang, et al.

    Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (COVID-ONE humoral immune). COVID-ONE humoral immunity is based on a dataset that contains the IgG/IgM responses to 21 of 28 known SARS-CoV-2 proteins and 197 spike protein peptides against 2,360 COVID-19 samples collected from 783 patients. In addition, 96 clinical parameters for the 2,360 samples and information for the 783 patients are integrated into the database. Furthermore, COVID-ONE humoral immune provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-humoral immune is freely available at www.COVID-ONE.cn .

  • Open Access

    COVID-ONE-humoral immune: The One-stop Database for COVID-19-specific Antibody Responses and Clinical Parameters

    by Zhaowei Xu, Yang Li, Qing Lei, Likun Huang, Dan-Yun Lai, Shu-Juan Guo, He-Wei Jiang, Hongyan Hou, Yun-Xiao Zheng, Xue-Ning Wang, et al.

    Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (COVID-ONE humoral immune). COVID-ONE humoral immunity is based on a dataset that contains the IgG/IgM responses to 21 of 28 known SARS-CoV-2 proteins and 197 spike protein peptides against 2,360 COVID-19 samples collected from 783 patients. In addition, 96 clinical parameters for the 2,360 samples and information for the 783 patients are integrated into the database. Furthermore, COVID-ONE humoral immune provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-humoral immune is freely available at www.COVID-ONE.cn .